concizumab
Selected indexed studies
- Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. (N Engl J Med, 2023) [PMID:37646676]
- Concizumab: First Approval. (Drugs, 2023) [PMID:37341887]
- Concizumab. (, 2006) [PMID:39836803]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. (2023) pubmed
- Concizumab: First Approval. (2023) pubmed
- Concizumab. (2006) pubmed
- Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. (2024) pubmed
- Concizumab, a Non-Replacement Therapy for Persons with Hemophilia with Inhibitors. (2025) pubmed
- Pharmacokinetic evaluation of concizumab for the treatment of hemophilia. (2025) pubmed
- Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives. (2022) pubmed
- Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. (2019) pubmed
- Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study. (2024) pubmed
- Concizumab improves clot formation in hemophilia A under flow. (2024) pubmed